BioSpace News Archive

TrialAssure, a leading pharmaceutical technology provider advancing clinical trial disclosure, data sharing, and transparency, announced that its flagship product TrialAssure ANONYMIZE®

Auburn Community Hospital is the first institution in the United States to integrate Abbott’s Alinity h‐series into the ACH Core Laboratory.

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Trivicta™ Hip System.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN) today reported financial results for the fourth quarter and full year ended December 31, 2023, provided updated guidance on parallel lead product candidates and highlighted pipeline progress.

Cognition Therapeutics, Inc., a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided corporate updates.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today provided a corporate update and reported financial results for the quarter and year ended December 31, 2023.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company’s first DDC to enter the clinic.